Bulk Pharmaceutical API Sources for SULFISOXAZOLE DIOLAMINE

Bulk Pharmaceutical API Sources for SULFISOXAZOLE DIOLAMINE

Vendor	Vendor Homepage	Vendor Sku	API Url
BOC Sciences		4299-60-9
BenchChem		B1195954
THE BioTek		bt-1537369
MedChemexpress MCE		HY-B0323A

Bulk Active Pharmaceutical Ingredient (API) Sources for: SULFISOXAZOLE DIOLAMINE

Last updated: August 4, 2025

---

Introduction

Sulfisoxazole Diolamine, an antibacterial sulfonamide, has historically been utilized to combat urinary tract infections and other bacterial maladies. As with numerous pharmaceuticals, sourcing high-quality bulk APIs like sulfisoxazole diolamine is critical for manufacturing efficacy, compliance with regulatory standards, and market competitiveness. This analysis explores primary sources, supply chain considerations, and the dynamic landscape influencing API procurement.

---

Overview of Sulfisoxazole Diolamine as an API

Sulfisoxazole diolamine is a sulfonamide antimicrobial characterized by its bacteriostatic activity. It functions by inhibiting folic acid synthesis in bacteria, thus impeding bacterial growth. Its pharmaceutical applications have decreased relative to newer agents but remain relevant in specific regional and niche therapeutic contexts.

From a manufacturing perspective, sulfisoxazole diolamine’s complexity involves synthesis pathways that require controlled chemical processes and high-purity starting materials. Accordingly, sourcing reliable suppliers with stringent quality standards remains essential for pharmaceutical companies.

---

Global API Manufacturing Landscape

Major Manufacturing Regions

The production of sulfisoxazole diolamine aligns with the global pharmaceutical excipient and API manufacturing hubs, notably:

• India: With a burgeoning generics sector and mature chemical manufacturing industry, India emerges as a primary source of sulfisoxazole diolamine. Leading firms leverage extensive R&D capabilities and a regulatory environment influenced by the Central Drugs Standard Control Organization (CDSCO).
• China: The country’s vast, integrated chemical and pharmaceutical manufacturing infrastructure actively supplies APIs globally. Chinese manufacturers benefit from economies of scale, competitive pricing, but face scrutiny over regulatory standards.
• European Union: Although smaller producers exist, European companies focus on high-quality, compliant APIs, often serving markets with strict regulatory regimes such as the U.S. FDA and EMA.

Key Manufacturers and Suppliers

Given the niche nature of sulfisoxazole diolamine, detailed supplier information is less centralized compared to blockbuster APIs. Notable entities include:

• Amneal Pharmaceuticals (USA): Although primarily a finished drug manufacturer, Amneal oversees some API procurement aligning with global standards.
• Sun Pharmaceutical Industries (India): A major producer of sulfonamide derivatives, including sulfisoxazole-based compounds—potentially supplying or partnering for the API.
• Teva Pharmaceuticals (Israel): Known for generic APIs, with manufacturing facilities compliant with international standards, possibly including sulfonamide derivatives.
• YuanMing Pharma (China): Active in synthetic APIs, including sulfonamide classes, with the capacity to produce sulfisoxazole diolamine under contract.

Contract Manufacturing and CMOs

Contract Manufacturing Organizations (CMOs) play pivotal roles in API supply, especially for niche APIs like sulfisoxazole diolamine. Several CMOs in India and China offer custom synthesis and bulk procurement, providing flexibility and scalability. Notable examples include:

• Hikal Ltd. (India): Offers custom synthesis of sulfonamides for pharma clients.
• BASF-YA (China): Provides comprehensive chemical manufacturing services, including APIs.

---

Quality and Regulatory Considerations

procuring sulfisoxazole diolamine mandates strict adherence to Good Manufacturing Practices (GMP). Suppliers must demonstrate compliance with authoritative agencies:

• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• World Health Organization (WHO) prequalification standards

Third-party audits and rigorous batch testing, including residual solvent analysis, purity validation, and impurity profiling, are critical before approval.

---

Supply Chain Challenges

The sourcing of sulfisoxazole diolamine faces several challenges:

• Raw Material Availability: The synthesis involves specific sulfonamide intermediates, which depend on the availability of high-purity chemicals. Supply chain disruptions in precursor chemicals can impact production stability.
• Regulatory Hurdles: Divergent international standards and evolving requirements influence supplier qualification processes.
• Price Volatility: Market demand fluctuations and geopolitical factors affect pricing dynamics.

To mitigate these risks, pharmaceutical companies often establish multi-source frameworks, prioritizing suppliers with demonstrated GMP compliance and robust QC protocols.

---

Emerging Trends and Future Outlook

• Localization and Nearshoring: Companies seek regional suppliers to reduce logistical complexities amid ongoing global supply chain disruptions.
• Increased Due Diligence: Regulatory agencies and clients emphasize supplier qualification programs, advancing transparency in sourcing practices.
• Sustainable Manufacturing: Environmental concerns drive the adoption of greener synthesis methods, influencing supplier selection toward environmentally compliant facilities.

While sulfisoxazole diolamine's niche status limits extensive market expansion, ongoing efforts in antibiotic stewardship and regional pharmaceutical needs suggest that reliable sources will remain vital for specific applications.

---

Conclusion

Sourcing sulfisoxazole diolamine as a bulk API involves navigating a complex, global supply chain composed predominantly of Indian, Chinese, and select European manufacturers. Ensuring compliance with GMP standards, validating supplier capabilities, and dynamically monitoring geopolitical and regulatory developments are essential practices for procurement success. As the landscape evolves, companies should establish multi-sourcing strategies, prioritize quality assurance, and stay attuned to emerging industry trends to secure reliable API supplies.

---

Key Takeaways

• India and China dominate the bulk API production landscape for sulfisoxazole diolamine, supported by extensive manufacturing capabilities and competitive pricing.
• Rigorous quality assurance and regulatory compliance (GMP, FDA, EMA) are non-negotiable in API sourcing, especially for antibiotics.
• Supply chain risks—raw material availability, geopolitical factors, and regulations—necessitate multi-source procurement strategies.
• Contract manufacturing organizations in Asia offer flexible, scalable options for sulfonamide APIs, with a focus on quality and cost efficiency.
• Emerging trends emphasize regional sourcing, green chemistry, and enhanced transparency to ensure a resilient supply of sulfisoxazole diolamine.

---

FAQs

1. What are the primary regions manufacturing sulfisoxazole diolamine?
   India and China are the leading producers, supported by established chemical and pharmaceutical industries. European manufacturers also supply high-quality APIs but on a smaller scale.

2. How do regulatory standards impact sourcing sulfisoxazole diolamine?
   Suppliers must meet GMP standards specified by agencies like the FDA and EMA; non-compliance risks regulatory rejection and quality issues.

3. Can I source sulfisoxazole diolamine from multiple suppliers?
   Yes, establishing multiple qualified sources minimizes supply disruptions and enhances procurement security.

4. What factors should I consider when selecting a sulfisoxazole diolamine supplier?
   Assess GMP compliance, quality control capabilities, supply stability, pricing, and regulatory track record.

5. Is the global supply of sulfisoxazole diolamine expected to increase?
   Given its limited current demand and antibiotic stewardship programs, supply growth is limited but could expand regionally based on specific market needs.

---

References

1. Indian Pharmacopoeia Commission. Indian Pharmacopoeia 2022.
2. European Medicines Agency. EudraLex—Volumes 1, 2, and 3.
3. U.S. Food and Drug Administration. Guidance for Industry: Chemistry, Manufacturing, and Controls.
4. Market research reports on global API manufacturing trends, 2022-2023.
5. Industry publications and company disclosures, 2023.

---

Note: This article is intended for informational purposes only and does not constitute an endorsement of specific suppliers or manufacturing capabilities.